[Focus: Drug-related osteonecrosis of the jaw].

[Focus: Drug-related osteonecrosis of the jaw].
Presse Med. 2017 Dec 21;:
Authors: Schmouchkovitch A, Remaud M, Simon H, Herry H, Le Toux G, Boisramé S
Abstract
Antiresorptives and antiangiogenics are treatments that have proven effective in oncology and the treatment of osteoporosis and they are increasingly prescribed. The care of these patients requires collaboration between the prescriber and the oral health professional to establish an optimized treatment plan. Therapeutic education of the patient is essential for him to understand the issues of good oral health and the adverse effects that can be caused by these treatments. The management is essentially based on the individual benefit/risk balance resulting from the general, local and inherent of the molecule risk factors. Management of drug-related osteonecrosis of the jaw should be as early as possible.
PMID: 29275972 [PubMed - as supplied by publisher]

Source: Presse Medicale - December 21, 2017 Category: General Medicine Authors: Schmouchkovitch A, Remaud M, Simon H, Herry H, Le Toux G, Boisramé S Tags: Presse Med Source Type: research